Atalanta Therapeutics secures $97 million to advance RNAi therapies for CNS diseases
- Atalanta Therapeutics completed a $97 million Series B financing to support Phase 1 trials for RNAi therapies targeting KCNT1-related epilepsy and Huntington’s disease.
- The financing was co-led by EQT Life Sciences and Sanofi Ventures, with participation from several other investors.
- The funds will help progress the therapies towards IND submissions and initiate Phase 1 trials.
- Atalanta's di-siRNA platform aims to deliver oligonucleotide therapies to the central nervous system.
Read more
Tris Pharma reports positive results for cebranopadol in intranasal abuse potential study
- Tris Pharma announced positive data from an intranasal human abuse potential study for cebranopadol, showing significantly lower abusability compared to oxycodone.
- The study involved nondependent recreational opioid users and demonstrated less drug liking for cebranopadol at a supratherapeutic dose.
- Cebranopadol, a dual-NMR agonist, showed slower absorption intranasally compared to orally, suggesting minimal nasal mucosa absorption.
- Tris plans to present full results at a medical congress and aims for a New Drug Application submission later this year.
Read more
